/
AXGN
$44.98+$0.05 (+0.10%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.4B
53M shares
52-week range
$10.50 – $46.00
97% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$23.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.9M | $106.7M | $112.3M | $127.4M | $138.6M | $159.0M | $187.3M | $225.2M |
| Cost of revenue | $12.9M | $17.3M | $21.6M | $22.9M | $29.8M | $37.1M | $45.4M | $57.9M |
| Gross profit | $71.0M | $89.4M | $90.7M | $104.4M | $108.8M | $121.9M | $142.0M | $167.4M |
| Gross margin | 84.6% | 83.7% | 80.8% | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| R&D | $11.8M | $17.5M | $17.8M | $24.2M | $25.6M | $27.3M | $27.8M | $32.9M |
| Operating income | −$20.5M | −$31.4M | −$23.2M | −$25.4M | −$29.7M | −$21.5M | −$3.3M | −$7.8M |
| EBITDA | −$20.3M | −$26.2M | −$19.3M | −$20.9M | −$23.5M | −$13.3M | $6.1M | $192.0K |
| Net income | −$22.4M | −$29.1M | −$23.8M | −$27.0M | −$28.9M | −$21.7M | −$10.0M | −$15.7M |
| Net margin | -26.7% | -27.3% | -21.2% | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| EPS (diluted) | -0.60 | -0.74 | -0.60 | -0.65 | -0.69 | -0.51 | -0.23 | -0.34 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $271M | $0.50 | $0.49–$0.51 | 5 |
| 2027 | $319M | $0.72 | $0.70–$0.73 | 4 |
| 2028 | $378M | $0.97 | $-1.11–$2.89 | 4 |
| 2029 | $445M | $1.06 | $1.04–$1.09 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Axogen, Inc. Common Stock
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
www.axogeninc.com- Employees
- 622
- IPO / List date
- Dec 17, 1986
- HQ
- ALACHUA, FL
Held by traders on TradeandTell
No one on the platform currently holds AXGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 142,000 | $1.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AXGN yet.
